EZH2 and non-small cell lung carcinoma: Similar is, FEZF1-AS1 decreases levels of P57 and E-cadherin in LAD (Lung adenocarcinoma) or NSCLC (Non-small-cell lung cancer) cells by recruiting RNA binding proteins EZH2 and LSD1 into their promoter regions, promoting malignant progression of cancers [14,16].